Next article Search Articles Instructions for authors  Access Statistics | Citation Manager  
CASE REPORT  

 Article Access Statistics
    Viewed493    
    Printed18    
    Emailed0    
    PDF Downloaded17    
    Comments [Add]    

Recommend this journal

Use of selexipag in a teenage patient with pulmonary arterial hypertension


1 Department of Pediatrics, Federal University of Rio de Janeiro, Rio de Janeiro, RJ; PEDICOR-Pediatric and Perinatal Cardiology Center, Sao Jose dos Campos, SP, Brazil
2 Pulmonary Hypertension Center, Faculty of Medical Sciences, Santa Casa de Sao Paulo, Sao Paulo, SP, Brazil
3 PEDICOR-Pediatric and Perinatal Cardiology Center, Sao Jose dos Campos, SP, Brazil

Correspondence Address:
Prof. Nathalie Jeanne Magioli Bravo-Valenzuela
Av. Andromeda, 693, s. 601-603, Zip Code: 12230-000, São José dos Campos- SP
Brazil
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/apc.APC_63_19

Rights and Permissions

Year : 2021  |  Volume : 14  |  Issue : 1  |  Page : 75-78

 

SEARCH
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles

  Article in PDF (832 KB)
Email article
Print Article
Add to My List
Pulmonary arterial hypertension (PAH) is a chronic, progressive, multifactorial disease. Currently, combination therapy is an attractive option for PAH management because three pathways (endothelin, nitric oxide, and prostacyclin) are involved in this disease. Selexipag is a novel oral prostacyclin pathway drug and is a highly selective IP prostacyclin receptor agonist with vasodilatory and antiproliferative effects. We report the case of a teenage patient with idiopathic PAH who presented in World Health Organization functional Class IV and showed no clinical improvement with dual therapy. We added oral selexipag to the treatment regimen and observed substantial improvement in her quality of life at the short-time follow-up. Despite the lack of childhood data regarding the use of selexipag in pediatric patients with PAH, the use of this drug in the current teenage patient improved her quality of life and exercise capacity.






[FULL TEXT] [PDF]*
 

 

 

 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 
 
 Reader Comments
 Email Alert *
  *
 * Requires registration (Free)
 
 CASE REPORT
 




1 Department of Pediatrics, Federal University of Rio de Janeiro, Rio de Janeiro, RJ; PEDICOR-Pediatric and Perinatal Cardiology Center, Sao Jose dos Campos, SP, Brazil
2 Pulmonary Hypertension Center, Faculty of Medical Sciences, Santa Casa de Sao Paulo, Sao Paulo, SP, Brazil
3 PEDICOR-Pediatric and Perinatal Cardiology Center, Sao Jose dos Campos, SP, Brazil

Correspondence Address:
Prof. Nathalie Jeanne Magioli Bravo-Valenzuela
Av. Andromeda, 693, s. 601-603, Zip Code: 12230-000, São José dos Campos- SP
Brazil
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/apc.APC_63_19

Rights and Permissions

Pulmonary arterial hypertension (PAH) is a chronic, progressive, multifactorial disease. Currently, combination therapy is an attractive option for PAH management because three pathways (endothelin, nitric oxide, and prostacyclin) are involved in this disease. Selexipag is a novel oral prostacyclin pathway drug and is a highly selective IP prostacyclin receptor agonist with vasodilatory and antiproliferative effects. We report the case of a teenage patient with idiopathic PAH who presented in World Health Organization functional Class IV and showed no clinical improvement with dual therapy. We added oral selexipag to the treatment regimen and observed substantial improvement in her quality of life at the short-time follow-up. Despite the lack of childhood data regarding the use of selexipag in pediatric patients with PAH, the use of this drug in the current teenage patient improved her quality of life and exercise capacity.






[FULL TEXT] [PDF]*


        
Print this article     Email this article